Dr Ira Spector has left his senior role at Allergan to join the clinical research organisation (CRO) Icon as executive VP, analytics and consulting.
Dr Spector was most recently senior VP of global development operations at Allergan where he spent four years. Prior to this he spent 17 years at Wyeth, leaving shortly after the company’s takeover by Pfizer.
In his new role at Icon Dr Spector will lead the company’s global consulting and drug development services and will also be responsible for Icon’s business process improvement and analytics capabilities.
Icon’s chief operating officer Dr Steve Cutler commented on the new appointment: “His extensive experience in managing some of the world’s largest trials in areas such as oncology, vaccines and CNS, coupled with his expertise in using technology to drive innovation and process improvement, will enable us to provide further strategic input to our customers’ drug and device programmes.”